Key result
Enlicitide earns FDA approval as the first oral PCSK9 inhibitor to lower LDL-C.
Answers are grounded in this paper and cite their sources.
Enlicitide is the first oral PCSK9 inhibitor approved by the FDA for LDL-C reduction, offering a non-injectable alternative for hypercholesterolemia management.
Enlicitide (Lipfendra – Merck), an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, has been approved by the FDA to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). It is the first oral PCSK9 inhibitor to be approved in the US; the other FDA-approved PCSK9 inhibitors (alirocumab [Praluent], evolocumab [Repatha], and lerodalcibep [Lerochol]) and the PCSK9-directed small interfering RNA inclisiran (Leqvio) are injected subcutaneously.1 Lipfendra was approved under the Commissioner's National Priority Voucher program, which accelerates the FDA review process for drugs that align with critical national health priorities.
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted a review in Hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Enlicitide (Lipfendra) was evaluated. Enlicitide (Lipfendra) is the first oral PCSK9 inhibitor approved by the FDA to reduce LDL-C in adults with hypercholesterolemia.
Synapse has enriched 10 related papers. Consider them for comparative context: